Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Acetylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | GMNN | O75496 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | BLM | P54132 | 3/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL29376874 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3259109 | 0.98 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL13323920 | 0.98 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL7079427 | 0.98 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2515409 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL20721036 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL4749513 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3004012 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL28744378 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL27571008 | 0.96 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4708655-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| EP-1257524-B1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2005-11-02 | — | — | EP | claimed |
| EP-1001760-B1 | COMPOSITION FOR CONTROLLING MOOD DISORDERS IN HEALTHY INDIVIDUALS | SIGMA TAU IND FARMACEUTI (IT) | 2005-02-02 | — | — | EP | claimed |
| US-6693215-B2 | TREATING CARNITINE CHLORIDE WITH AN ION EXCHANGER TO FORM AN INNER SALT IN AQUEOUS SOLUTION BEFORE REACTING WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-02-17 | — | — | US | claimed |
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-10 | — | — | US | claimed |
| EP-1171111-B1 | GRANULATE WITH HIGH CONTENT OF L-CARNITINE OR AN ALKANOYL L-CARNITINE, PARTICULARLY SUITABLE FOR THE PRODUCTION OF TABLETS BY DIRECT COMPRESSION | BIOSINT S P A (IT) | 2003-05-02 | — | — | EP | claimed |
| US-6485741-B2 | Granulate with high content of L-carnitine or an alkanoyl L-carnitine | BIOSINT S.P.A. (IT) | 2002-11-26 | — | — | US | claimed |
| JP-2002540153-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1257524-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-11-20 | — | — | EP | claimed |
| US-20020025984-A1 | Granulate with high content of L-carnitine or an alkanoyl L-carnitine, particularly suitable for the production of tablets by direct compression | BIOSINT S.P.A. | 2002-02-28 | — | — | US | claimed |
| EP-1171111-A2 | GRANULATE WITH HIGH CONTENT OF L-CARNITINE OR AN ALKANOYL L-CARNITINE | Biosint S.p.A. (IT) | 2002-01-16 | — | — | EP | claimed |
| US-6335021-B1 | ACETYL L-CARNITINE AND SALTS, 5HYDROXY-TRYPTOPHANE, EXCIPIENTS; ANTIDEPRESSANTS; STRESS RELIEVING; SIDE EFFECTS REDUCTION; EATING DISORDERS AND NERVOUS SYSTEM DISORDERS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| WO-2001058850-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| WO-2000057873-A2 | GRANULATE WITH HIGH CONTENT OF L-CARNITINE OR AN ALKANOYL L-CARNITINE | BIOSINT S.P.A. (IT) | 2000-10-05 | — | — | WO | claimed |
| EP-1001760-A1 | COMPOSITION FOR CONTROLLING MOOD DISORDERS IN HEALTHY INDIVIDUALS | Sigma-Tau Healthscience S.p.A. (IT) | 2000-05-24 | — | — | EP | claimed |
| US-6066664-A | ADMINISTERING 5-HYDROXYTRYPTOPHAN AND AN ALKANOYL L-CARNITINE WHERE THE ALKANOYL HAS 2-6 CARBON ATOMS, OR SALT THEREOF | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-05-23 | — | — | US | claimed |
| WO-1998057629-A1 | COMPOSITION FOR CONTROLLING MOOD DISORDERS IN HEALTHY INDIVIDUALS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1998-12-23 | — | — | WO | claimed |
| WO-1998055117-A1 | METHOD FOR DECREASING THE APPETITE IN BULIMIC, OVERWEIGHT INDIVIDUALS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-12-10 | — | — | WO | claimed |
| EP-0220538-B1 | NEW PANTOTHENYL DERIVATIVES | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1990-07-04 | — | — | EP | claimed |
| EP-0220538-A1 | New pantothenyl derivatives | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1987-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | CRAT, SLC25A20, MUC1 | CHRM2 683/4885CHRM1 861/4885LMNA 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.